17:00 - 13.11.2025

---

November 13, Fineko/abc.az. Pfizer has announced the sale of the remaining stake in BioNTech. The sale is carried out through the placement of depository receipts in the amount of 4.55 million at a price of $108–$111.70 per paper.

ABC.AZ informs that following a drop in COVID-19 vaccine revenue, Pfizer announced plans to sell its remaining stake in BioNTech. According to the terms of the placement, about 4.55 million American BioNTech depositary receipts will be put on the market at the price of $108–$111.70 per unit. The transaction volume may reach $508 million.

The partnership between Pfizer and BioNTech during the pandemic brought the companies multibillion-dollar revenues and ensured the supply of vaccines to the U.S. and Europe. As part of the collaboration, Pfizer acquired a stake in BioNTech and is still working with the German company on updated vaccine formulas. At the same time, the decline in global demand for COVID-19 drugs led to a decrease in revenue. This forced Pfizer to review its asset structure and investment priorities.